上海金畔生物科技有限公司提供Gibco™ CTS™ OpTmizer™ T Cell Expansion SFM, bag fo ，欢迎访问官网了解更多产品信息和订购。
Gibco™ CTS™ OpTmizer™ T Cell Expansion SFM, bag fo

Gibco™ CTS™ OpTmizer™ T Cell Expansion SFM, bag format

Versatile T Cell Culture Media:

OpTmizer™ CTS™ T-Cell Expansion SFM is designed to give results equivalent to conventional serum-supplemented media. However, if desired, 2% heat-inactivated human serum (Cat. No. 34005-100) may be added to the medium to enhance viability and expansion. The use of serum, and the amount required, should be determined empirically depending on the specific T-cell culture application.

Ready for T Cell Expansion:

OpTmizer™ CTS™ T-Cell Expansion SFM is designed for the expansion of human T-cells permitting CD3+ densities of >3×106 cells/mL in static conditions and >2×107 cells/mL in WAVE bags. Results may vary depending on the T-cell subset (e.g., Ag-specific cells). Conditions for specific T-cell culture applications should be determined empirically.

Stability of Complete Media:

Complete OpTmizer™ CTS™ T-Cell Expansion SFM (basal, supplement, and L-glutamine) is stable for 4 weeks when stored in the dark at 2–8°C.

Simplify Your Transition into Clinical Research:

The Gibco™ Cell Therapy Systems (CTS™) brand offers a broad array of products for use in cell therapy applications, including media, reagents, growth factors, enzymes, cell selection/expansion reagents, and devices. Gibco™ CTS™ products deliver:

• Reduced burden in qualifying reagents

• Appropriate certificates of analyses and origin included

• Convenient access to our Drug Master File (DMF)

上海金畔生物科技有限公司提供Gibco™ CTS™ OpTmizer™ T-Cell Expansion SFM, no phe ，欢迎访问官网了解更多产品信息和订购。
Gibco™ CTS™ OpTmizer™ T-Cell Expansion SFM, no phe

Gibco™ CTS™ OpTmizer™ T-Cell Expansion SFM, no phenol red, bag format

CTS OpTmizer T-Cell Expansion SFM is available with and without phenol red. This version of CTS OpTmizer SFM lacks phenol red, and is available in both bottle and bag format.

Features of CTS OpTmizer T-Cell Expansion SFM include:

• Supports high-density T cell culture (>4 x 106 CD3+ T-cells/mL)

• Supports T-cell activation using Dynabeads magnetic beads, soluble antibodies, and stimulatory antibody-presenting cell protocols

• Similar phenotype, function (e.g., cytokine secretion profile), and viability to T-cells cultured with conventional human AB serum-supplemented medium

• Supports a T-cell phenotype similar to human serum-supplemented medium

• Demonstrates enhanced efficacy and persistence of CART-19 cells when grown in medium supplemented with CTS Immune Cell Serum Replacement (ICSR)

Demonstrated functional performance:

Cells grown in CTS OpTmizer T-Cell Expansion SFM with or without human serum demonstrate good cytokine production profiles in polyclonally activated T cells. CTS OpTmizer T-Cell Expansion SFM maintains the desired the CD62L+ central memory T-cell phenotype.

GMP manufactured:

The primary manufacturing site for CTS OpTmizer T-Cell Expansion SFM is FDA-registered and has an ISO13485-certified quality management system. The methods and controls used for the manufacturing are in conformity with current Good Manufacturing Practices for medical devices, 21 CFR Part 820, of the regulation. Alternate manufacturing sites are available, providing risk mitigation by helping to ensure security of supply.

Versatility:

CTS OpTmizer T-Cell Expansion SFM has been widely adopted in clinical T-cell research applications including the culture of CAR T-cells. It works with multiple culture formats, including culture flasks, culture bags, and rocking bioreactor systems. CTS OpTmizer T-Cell Expansion SFM was designed to support expansion of cultured human T-cells without additional serum supplementation. Increased performance is generally observed when supplemented with CTS Immune Cell Serum Replacement.

上海金畔生物科技有限公司提供Gibco™ CTS™ OpTmizer™ T-Cell Expansion SFM (RUO) ，欢迎访问官网了解更多产品信息和订购。
Gibco™ CTS™ OpTmizer™ T-Cell Expansion SFM (RUO)

Gibco™ CTS™ OpTmizer™ T-Cell Expansion SFM (RUO)

This Research Use Only product is based on our therapeutic grade CTS AIM V SFM , which is an FDA 510(k) cleared device in the U.S. intended for human ex-vivo tissue and cell culture processing applications.

This Gibco CTS OpTmizer T-Cell Expansion SFM supports the growth and expansion of human T lymphocytes and is for research use only. It is a complete serum-free, xeno-free medium consisting of CTS OpTmizer T-Cell Expansion Basal Medium and CTS OpTmizer T-Cell Expansion Auxiliary Concentrated Medium, which are mixed together prior to use. Supplementation with cytokines per the specific procedure and L-glutamine is necessary and should be done aseptically immediately prior to use of the medium.

• Based on a proven medium

• Supports high-density T cell culture (>3 x 106 CD3+ T cells/mL) in static culture and WAVE Bioreactor systems, including CAR-T cells

• Supports T cell activation using Dynabeads magnetic beads and stimulatory antibody-presenting cell protocols

• Similar phenotype, function, and viability (e.g., cytokine secretion profile) to T cells cultured with conventional human AB serum–supplemented medium

• Supports a T cell phenotype (CD4, CD8, and CD62L) similar to human serum-supplemented medium [1]

• Demonstrates enhanced efficacy and persistence of CART-19 cells when grown in medium supplemented with CTS Immune Cell Serum Replacement (ICSR) medium

Based on a proven medium:

CTS OpTmizer T-Cell Expansion SFM for research use only is based on the same formulation as therapeutic-grade CTS OpTmizer T-Cell Expansion SFM, which is an FDA-cleared medium used in immunotherapy applications in the United States. It is currently used as an ancillary reagent in CAR-T immunotherapy clinical trials.

Demonstrated functional performance and In vivo efficacy:

Cells grown in CTS OpTmizer T-Cell Expansion SFM with or without human serum demonstrate good cytokine production profiles in polyclonally activated T cells. CTS OpTmizer T-Cell Expansion SFM maintains the desired CD8+ CAR-T cell phenotype and the CD62L+ central memory T cell expression. CAR-T cells expanded in CTS OpTmizer T-Cell Expansion SFM and injected into leukemic mouse models demonstrated improved CAR-T cell efficacy with reduced tumor burden out to day 49 compared to competitor media.

GMP manufactured:

The primary manufacturing site for CTS OpTmizer T-Cell Expansion SFM is FDA-registered and has an ISO13485-certified quality management system. The methods and controls used for the manufacturing are in conformity with current Good Manufacturing Practices for medical devices, 21 CFR Part 820, of the regulation. Alternate manufacturing sites are available, providing risk mitigation by helping to ensure security of supply.

Versatility:

CTS OpTmizer T-Cell Expansion SFM has been widely adopted in clinical T cell research applications including the culture of CAR T cells. It works with multiple culture formats, including culture flasks and WAVE Bioreactor systems. CTS OpTmizer T-Cell Expansion SFM was designed to support expansion of cultured human T cells without additional serum supplementation. However, superior performance may be observed when supplemented with either human AB serum or CTS Immune Cell Serum Replacement.